| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972377 | JANSSEN PHARMS | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
Jun, 2015
(8 years ago) | |
| US5876746 | JANSSEN PHARMS | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
Nov, 2015
(8 years ago) | |
Ortho Evra is owned by Janssen Pharms.
Ortho Evra contains Ethinyl Estradiol; Norelgestromin.
Ortho Evra has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ortho Evra are:
- US5972377
- US5876746
Ortho Evra was authorised for market use on 20 November, 2001.
Ortho Evra is available in film, extended release;transdermal dosage forms.
Ortho Evra can be used as prevention of ovulation in a woman.
The generics of Ortho Evra are possible to be released after 20 November, 2015.
Drugs and Companies using ETHINYL ESTRADIOL; NORELGESTROMIN ingredient
Market Authorisation Date: 20 November, 2001
Treatment: Prevention of ovulation in a woman
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
How can I launch a generic of ORTHO EVRA before it's drug patent expiration?
More Information on Dosage
ORTHO EVRA family patents
